Latest Kidney Cancer News
Kidney Cancer News elsewhere on the Web
In a groundbreaking pooled analysis published in the British Journal of Cancer, researchers from the German AIO Study Group have elucidated the complex interplay between steroid and antibiotic
MIAMI BEACH, FL – Cancer-specific outcomes have been significantly improved by therapies treating advanced renal cell carcinoma (RCC) with distant metastasis. Those patients remain at increased risk of cardiovascular disease (CVD) and related events, however. A new study published in Cancer ...
Clear cell renal cell carcinoma (ccRCC) stands as the most prevalent and aggressive subtype of kidney cancer, presenting formidable challenges in clinical management due to its high rates of
In this forward-looking segment on advanced renal cell carcinoma, Dr. Ornstein asks the panel to consider how treatment decisions may evolve if newer combination therapies become available in the second-line setting. He introduces the potential role of lenvatinib combined with belzutifan and ...
Hypoxia-inducible factor 2α (HIF2α), a transcription factor pivotal to cellular adaptation under low oxygen conditions, has long stood as a formidable therapeutic challenge. Its designation as “
... partial nephrectomy (RAPN) may be a safe alternative to minimally invasive radical nephrectomy in select patients with cT2 renal cell carcinoma (RCC).
... renal cell carcinoma (RCC). Investigators compared cancer-specific survival rates after synchronous vs metachronous metastasis in patients with ...
Less invasive ablation treatment in patients with small renal tumors has a comparable risk for tumor progression to surgical resection, with fewer complications and shorter hospital stays.
Sara Coca Membribes: KIM1 in Advanced RCC Published in European Urology / Begoña P Valderrama, cancer, Charles Mein, Charlotte Ackermann, Cristina Suárez,
Experts discussed the clinical implications of the LITESPARK-011 trial of belzutifan plus lenvatinib following a presentation of efficacy findings at ASCO GU.
No results found.
Articles from Kidney Cancer UK
Kidney Cancer UK Paper Published in BJU International
A decade-long insight into patient views on kidney cancer care delivery
A paper on our Kidney Cancer UK 10-Year ...
First NKCA annual report recommends reduction in unwarranted variation
The first annual State of the Nation Report from the National Kidney Cancer Audit (NKCA) highlights unwarranted ...
ITM Obtains Exclusive Worldwide License from Debiopharm for CA IX-Targeted Peptide-based Radiopharmaceutical Programs Targeting Solid Tumors
"Patients with advanced renal cancer often have a long and difficult ... kidney cancer," added Darren R. Feldman, MD, Medical Oncologist ...
Dr McGregor on the Updated NCCN Guidelines for Non–Clear Cell RCC
Bradley McGregor, MD, discusses the current NCCN guideline recommendations for the treatment of patients with divergent RCC histologies.
Belzutifan Improves PFS in ccRCC Subgroups
Findings from a subgroup analysis of the phase 3 LITESPARK-005 trial showed that belzutifan demonstrated superior efficacy and safety outcomes vs everolimus across prespecified subgroups.
No results found.